51 related articles for article (PubMed ID: 7696175)
1. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression.
Miller DL; el-Ashry D; Cheville AL; Liu Y; McLeskey SW; Kern FG
Cell Growth Differ; 1994 Dec; 5(12):1263-74. PubMed ID: 7696175
[TBL] [Abstract][Full Text] [Related]
2. Intracellular lipid droplet accumulation occurs early following viral infection and is required for an efficient interferon response.
Monson EA; Crosse KM; Duan M; Chen W; O'Shea RD; Wakim LM; Carr JM; Whelan DR; Helbig KJ
Nat Commun; 2021 Jul; 12(1):4303. PubMed ID: 34262037
[TBL] [Abstract][Full Text] [Related]
3. Preparation and Characterization of MUC-30-Loaded Polymeric Micelles against MCF-7 Cell Lines Using Molecular Docking Methods and In Vitro Study.
Nasongkla N; Tuchinda P; Munyoo B; Eawsakul K
Evid Based Complement Alternat Med; 2021; 2021():5597681. PubMed ID: 34135981
[TBL] [Abstract][Full Text] [Related]
4. Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases.
Sommer AK; Hermawan A; Mickler FM; Ljepoja B; Knyazev P; Bräuchle C; Ullrich A; Wagner E; Roidl A
Oncotarget; 2016 Aug; 7(31):50461-50476. PubMed ID: 27409163
[TBL] [Abstract][Full Text] [Related]
5. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.
Jeselsohn R; Barry WT; Migliaccio I; Biagioni C; Zhao J; De Tribolet-Hardy J; Guarducci C; Bonechi M; Laing N; Winer EP; Brown M; Leo AD; Malorni L
Clin Cancer Res; 2016 Dec; 22(23):5755-5764. PubMed ID: 27185372
[TBL] [Abstract][Full Text] [Related]
6. EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
De Andrade JP; Park JM; Gu VW; Woodfield GW; Kulak MV; Lorenzen AW; Wu VT; Van Dorin SE; Spanheimer PM; Weigel RJ
Mol Cancer Ther; 2016 Mar; 15(3):503-11. PubMed ID: 26832794
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.
Zhao M; Ramaswamy B
World J Clin Oncol; 2014 Aug; 5(3):248-62. PubMed ID: 25114842
[TBL] [Abstract][Full Text] [Related]
8. Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells.
Chen C; Baumann WT; Clarke R; Tyson JJ
FEBS Lett; 2013 Oct; 587(20):3327-34. PubMed ID: 23994522
[TBL] [Abstract][Full Text] [Related]
9. Zinc and cancer: implications for LIV-1 in breast cancer.
Grattan BJ; Freake HC
Nutrients; 2012 Jul; 4(7):648-75. PubMed ID: 22852056
[TBL] [Abstract][Full Text] [Related]
10. Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.
Moi LL; Flågeng MH; Gjerde J; Madsen A; Røst TH; Gudbrandsen OA; Lien EA; Mellgren G
BMC Cancer; 2012 Jun; 12():247. PubMed ID: 22703232
[TBL] [Abstract][Full Text] [Related]
11. Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells.
Tyson JJ; Baumann WT; Chen C; Verdugo A; Tavassoly I; Wang Y; Weiner LM; Clarke R
Nat Rev Cancer; 2011 Jun; 11(7):523-32. PubMed ID: 21677677
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy.
Saxena NK; Sharma D
Mol Cell Pharmacol; 2010; 2(5):191-202. PubMed ID: 21499573
[TBL] [Abstract][Full Text] [Related]
13. Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors.
Brodie A; Sabnis G
Clin Cancer Res; 2011 Jul; 17(13):4208-13. PubMed ID: 21415222
[TBL] [Abstract][Full Text] [Related]
14. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.
Toneff MJ; Du Z; Dong J; Huang J; Sinai P; Forman J; Hilsenbeck S; Schiff R; Huang S; Li Y
Neoplasia; 2010 Sep; 12(9):718-26. PubMed ID: 20824048
[TBL] [Abstract][Full Text] [Related]
15. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers.
Brinkman JA; El-Ashry D
J Mammary Gland Biol Neoplasia; 2009 Mar; 14(1):67-78. PubMed ID: 19263197
[TBL] [Abstract][Full Text] [Related]
16. Calmodulin modulates Akt activity in human breast cancer cell lines.
Coticchia CM; Revankar CM; Deb TB; Dickson RB; Johnson MD
Breast Cancer Res Treat; 2009 Jun; 115(3):545-60. PubMed ID: 18587642
[TBL] [Abstract][Full Text] [Related]
17. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
Nicholson RI; Hutcheson IR; Jones HE; Hiscox SE; Giles M; Taylor KM; Gee JM
Rev Endocr Metab Disord; 2007 Sep; 8(3):241-53. PubMed ID: 17486454
[TBL] [Abstract][Full Text] [Related]
18. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.
Allred DC; Brown P; Medina D
Breast Cancer Res; 2004; 6(6):240-5. PubMed ID: 15535853
[TBL] [Abstract][Full Text] [Related]
19. Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice.
Sharp JA; Waltham M; Williams ED; Henderson MA; Thompson EW
Clin Exp Metastasis; 2004; 21(1):19-29. PubMed ID: 15065599
[TBL] [Abstract][Full Text] [Related]
20. Inducible expression of FGF-3 in mouse mammary gland.
Ngan ES; Ma ZQ; Chua SS; DeMayo FJ; Tsai SY
Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11187-92. PubMed ID: 12169667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
